Company Description
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States.
It operates in three segments: Device Protection, Women’s Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes.
It also provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material used to repair or reconstruct the peripheral vasculature.
In addition, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction.
It serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors.
The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023.
Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
| Country | United States |
| Founded | 2015 |
| IPO Date | Oct 8, 2020 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 51 |
| CEO | C. Mills |
Contact Details
Address: 12510 Prosperity Drive, Suite 370 Silver Spring, Maryland 20904 United States | |
| Phone | 240 247 1170 |
| Website | elutia.com |
Stock Details
| Ticker Symbol | ELUT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001708527 |
| ISIN Number | US05479K1060 |
| Employer ID | 47-4790334 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. C. Randal Mills Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Matthew B. Ferguson | Chief Financial Officer |
| Dr. Michelle LeRoux Williams Ph.D. | Chief Scientific Officer |
| Courtney Guyer | Vice President of Marketing |
| Dr. Sonali Fonseca Ph.D. | Vice President and Head of Emerging Businesses |
| Jeffry D. Hamet | Senior Vice President of Finance, Treasurer and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2025 | 424B5 | Filing |
| Apr 7, 2025 | EFFECT | Notice of Effectiveness |
| Apr 4, 2025 | ARS | Filing |
| Apr 4, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 18, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 13, 2025 | SCHEDULE 13D/A | Filing |
| Mar 11, 2025 | 10-K | Annual Report |
| Mar 6, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |